Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Aug 3:31:e948180.
doi: 10.12659/MSM.948180.

Mechanisms of Leydig Cell Aging and Obesity-Related Hypogonadism in Men: A Review

Affiliations
Review

Mechanisms of Leydig Cell Aging and Obesity-Related Hypogonadism in Men: A Review

Xinshuang Huang et al. Med Sci Monit. .

Abstract

The rising prevalence of overweight, obesity, and late-onset hypogonadism (LOH) is seriously affecting the quality of life of middle-aged and older men. LOH is a testosterone deficiency syndrome that is closely associated with aging. Its main symptoms are erectile dysfunction, loss of libido, fatigue, and loss of bone density. Testicular Leydig cells are located in the connective tissue between the spermatogenic tubules and are the primary sites producing testosterone. Metabolic disorders such as obesity and hyperlipidemia accelerate Leydig cell aging, reduce testosterone levels, and contribute to the development of LOH. The pathogenesis of LOH mainly includes oxidative stress, inflammation, mitochondrial dysfunction, and endoplasmic reticulum stress. The treatments for LOH include testosterone replacement therapy, senolytic therapy, stem cell therapy, and traditional Chinese medicine therapy. Obesity may be one of the important mechanisms of obesity-related LOH by promoting Leydig cell aging, changing the endocrine environment, and worsening chronic inflammation, and research in this field is still deepening. Therefore, this article reviews the mechanisms of testicular interstitial cell senescence and obesity-related delayed hypogonadism, as well as possible obesity management methods.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: None declared

Figures

Figure 1
Figure 1
Mechanisms of testicular leydig cell senescence in obesity-related late-onset hypogonadism. Illustration: From left to right, they are endoplasmic reticulum stress, oxidative stress, senescence-associated secretory phenotype (SASP), cellular senescence, hypothalamic-pituitary-gonadal axis injury, immune cell activation, autophagy, and mitochondrial dysfunction in sequence. In the middle is the process of obesity – aging – testicular Leydig cell dysfunction.
Figure 2
Figure 2
Treatment of testicular leydig cell senescence in obesity-related late-onset hypogonadism. Illustration: From left to right are exercise therapy, stem cell therapy, traditional Chinese medicine therapy, drug therapy, and testosterone replacement therapy (TRT). In the middle is the process of obesity – aging – testicular Leydig cell dysfunction.

Similar articles

References

    1. De Mattos K, Viger RS, Tremblay JJ. Transcription factors in the regulation of Leydig cell gene expression and function. Front Endocrinol (Lausanne) 2022;13:881309. - PMC - PubMed
    1. Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107–17. - PubMed
    1. Zhao D, Guallar E. Testosterone and cardiovascular disease in men. Ann Intern Med. 2022;175(2):287–88. - PubMed
    1. Guan X, Chen P, Ji M, et al. Identification of rat testicular Leydig precursor cells by single-cell-RNA-sequence analysis. Front Cell Dev Biol. 2022;10:805249. - PMC - PubMed
    1. Zirkin BR, Papadopoulos V. Leydig cells: Formation, function, and regulation. Biol Reprod. 2018;99(1):101–11. - PMC - PubMed

LinkOut - more resources